Nuichuang Medical Files IPO Prospectus: A Global Pioneer in Pan-Vascular Interventional Devices

Pan-vascular intervention has long been a key focus of China’s healthcare sector. In recent years, innovative pan-vascular interventional medical devices have received strong policy support from the Chinese government.

National policies have not only explicitly incorporated the development of innovative medical devices, such as vascular interventional devices, into multiple Five-Year Plans and implemented favorable policies that temporarily exclude them from centralized procurement, but have also accelerated the review and approval processes to encourage the substitution of imported products with domestically produced medical devices.

Regulatory Policies for Vascular Interventional Medical Devices in China

Data sourced from Frost & Sullivan analysis

Supported by favorable policies, China’s pan-vascular intervention sector has continued to develop positively, giving rise to a number of outstanding domestic manufacturers. Chengdu Newtron Medical Device Co., Ltd. (hereinafter referred to as “Newtron Medical”) is a dark horse in this field.

Since its establishment in April 2021, the company has maintained a steady growth trajectory. Within just one year of its founding, several Class III medical devices obtained type testing reports. In 2022, the company secured five Class III medical device registration certificates and successfully launched China’s first domestically produced “coronary papillary balloon catheter.”

Entering 2023, the company had achieved commercialization capabilities, with cumulative revenue reaching tens of millions of yuan. As of Q1 2025, clinical trials for its independently developed flow-diverting stents with anticoagulant coating and intracranial drug-coated balloon catheters have completed patient enrollment, and the total number of Class III medical device registration certificates obtained has reached nine.

In addition, the key special project on “Diagnostic and Therapeutic Equipment and Biomedical Materials” under the National Key R&D Program for 2024 was officially approved this year. Among these initiatives, the project titled “Research and Development of Medical Devices and Equipment for Cerebrovascular Intervention/Implantation” is led by Newcare Medical. This project focuses on the development of core technologies for intracranial flow diverter devices and drug-coated balloon catheters.

VCBeat leverages DeepSeek to analyze Newcare Medical’s development, exploring how the most popular large AI model views this rapidly rising enterprise in the field of pan-vascular intervention.

Newwin Medical is an innovative medical device company with significant technological advantages and strategic foresight. Its core strengths and development potential are reflected in the following aspects:

1. Market Positioning and Differentiated Competition

• Market Selection: Leveraging neurointervention as an entry point to avoid red-ocean competition, followed by expansion into coronary and peripheral vascular fields to establish a “pan-vascular intervention” portfolio. As an emerging sector with few mature domestic players, neurointervention offers a window of opportunity for rapid growth.

• Differentiated Products: Developed China’s first coronary papillary balloon catheter and the world’s first peripheral papillary balloon, featuring high technical complexity and significant clinical value.

2. Technical Barriers and Innovation Capability

• Independent R&D Capabilities: Core processes and equipment are independently developed, breaking through industry technical bottlenecks. For example, the manufacturing process for coronary papillary balloons has resolved a long-standing challenge that peers had struggled with for years.

• Proactive Product Portfolio Strategy:

• Anticoagulant and Endothelialization-Promoting Flow Diverter: The first domestic product combining anticoagulant and endothelialization-promoting functions, with the potential to rewrite clinical guidelines.

• Intracranial Drug-Coated Balloon: No comparable products with similar indications are available globally; it has demonstrated impressive clinical data in addressing intracranial arterial stenosis, which is highly prevalent in Asia.

• Biodegradable Flow Diverter Stent: Animal studies have been completed, with performance far exceeding expectations; preclinical research is planned to be advanced.

3. Commercialization Capability

• Rapid Revenue Growth: Established just three years ago, the company achieved over RMB 40 million in revenue in 2024, realizing “sales upon certification” driven by both product stability and market strategy.

• Channel Integration Capability: By introducing seasoned strategic partners from the industry and leveraging the team’s clinical resources, we rapidly penetrate the market and establish a sales network.

4. Core Team

• The founding team has an average of over 10 years of industry experience, covering the entire value chain from R&D, manufacturing, and clinical trials to sales. The founder has been deeply engaged in the cardiovascular field for nearly 20 years, with substantial technical expertise.
  

• The team demonstrates outstanding cross-disciplinary collaboration capabilities, forming a unique advantage in technological integration.

5. Strategic Planning and Industry Recognition

• Comprehensive Product Portfolio: The company plans to establish a full suite of products in the field of neurointervention, benchmarking against leading domestic and international enterprises, while simultaneously addressing weaknesses in its coronary and peripheral vascular product lines.

• National-Level Project Endorsement: Spearheaded the National Key R&D Program project titled “Research and Development of Medical Materials and Equipment for Cerebrovascular Intervention/Implantation,” standing as the sole private enterprise in Sichuan Province selected for this initiative, underscoring its technological prowess.

6. Summary

Newtron Medical demonstrates strong competitiveness in the pan-vascular intervention field, leveraging three core advantages: differentiated technological barriers, efficient commercialization, and a seasoned team. The successful launch of its innovative products holds the potential to break the monopoly of imported devices and even drive transformative changes in clinical practice. By balancing innovation with risk management and refining its product ecosystem, the company is well-positioned to emerge as a leading enterprise in this niche sector.

DeepSeek believes that if Newcare Medical can continuously improve its product ecosystem, it is highly likely to grow into a leading enterprise in its niche sector. Currently, Newcare Medical is steadily building and refining its product pipeline.

At its inception, Neuvo Medical entered the neurointerventional space when it was still an emerging field in China, with few established players, whereas coronary and peripheral vascular interventions had already become hyper-competitive red oceans. Consequently, Neuvo Medical chose neurointervention as its entry point, gradually expanding into the coronary and peripheral sectors to form“Neurology-focused, with coronary and peripheral support”strategic layout.

In the field of neurointervention, Newborn Medical has built a comprehensive product portfolio centered around the two major clinical scenarios of “ischemia” and “hemorrhage.” Among them,"Anticoagulant Flow-Diverter Stent" and "Intracranial Drug-Coated Balloon Catheter"Both products hold significant clinical value.

The former is the world’s first intracranial stent with both anticoagulant and endothelialization-promoting functions., aimed at addressing the pain point of traditional bare-metal stents being prone to thrombosis;The latter targets intracranial arterial stenosis, a condition with high prevalence among Asian populations.Filling a global gap. It is reported that both products have completed clinical enrollment,Expected to be approved for market launch by the end of 2025.

In the coronary and peripheral fields,Newborns did not choose to compete head-on with leading companies, but instead focused on “small and beautiful” innovative products.

Its independently developedCoronary Papillary Balloon Catheter: The first domestically produced functional balloon capable of both pre-dilation and post-dilation, resolving the challenge of uneven stent expansion associated with traditional balloons.The product was approved in late 2022 and has demonstrated significant advantages in clinical practice. The company’s independently developedThe World's First Peripheral Mastoid Balloon Dilation Catheter, it can be used for percutaneous transluminal angioplasty of the peripheral vascular system, as well as for the dilation of stenoses in autogenous or synthetic arteriovenous dialysis fistulas, thereby delivering greater dilating pressure to the pathological lesions and improving the success rate of surgical procedures.

In the medical device industry, technological breakthroughs often entail lengthy R&D cycles and high trial-and-error costs. Newcare Medical’s ability to achieve multiple “first-in-China” and even “first-in-the-world” milestones within a short period is closely tied to the technical expertise accumulated by its core team and the establishment of its proprietary technology platform.

The Newtron team took a novel approach, overcoming numerous challenges through customized equipment and proprietary processes. “We drew the equipment blueprints ourselves and determined the process parameters through repeated trial and error, with no existing experience to reference,” Gao Fei, founder of Newtron Medical, told VCBeat.

Similar cross-disciplinary technological integration is also evident in anticoagulant flow-diverting dense-mesh stents. This product adoptsSpecial coating technology that both inhibits thrombus formation and promotes vascular endothelialization, thereby enhancing biocompatibility.Gao Fei revealed that the inspiration for this technology stemmed from his early accumulation of research in cardiovascular anticoagulation. “Some team members had previously participated in the R&D of devices for structural heart disease, and these experiences helped us avoid many detours.”

Notably, Newborn Medical is attempting to reshape clinical guidelines through its innovative products. Its intracranial drug-coated balloon, designed for intracranial stenosis—a condition with high prevalence among East Asian populations—has completed a multicenter, randomized, double-blind trial. Follow-up data demonstrate that its efficacy is significantly superior to that of existing therapies.

In the medical device industry, obtaining regulatory approval is notoriously difficult, and many startups fail not because they cannot get approved, but because their products do not sell after approval. However, Newcare Medical has achieved “sales upon approval.” In August 2022, its first neurointerventional product received regulatory clearance; within the same year, it was listed for procurement in hospitals across 90% of China’s provinces, and its revenue exceeded RMB 20 million the following year. This success stems from the team’s rigorous control over the entire product lifecycle.

How Does Newcare Medical Achieve This?

First, during the product development phase, Newcare Medical has consistently adopted a clinical needs-oriented approach, with project initiation always rooted in addressing clinical pain points. For instance, the development of intracranial drug-coated balloons was driven by the unique pathological characteristics of Asian patients, while coronary papillary balloons were designed to tackle the clinical challenge of uneven expansion following stent implantation. Furthermore, most of the company’s product managers have clinical backgrounds, and they engage in iterative consultations with experts throughout the R&D process to ensure that the products genuinely meet physicians’ needs.

Secondly, during the production phase, the company ensures both quality and stability. All core production equipment is independently designed, thereby guaranteeing process stability from the source.

Finally, in the sales phase, Newtron adopted a “dual-track” strategy. On one hand, it gradually expanded its market presence through traditional distribution channels; on the other hand, it brought in industry veterans as strategic partners, leveraging their resources to rapidly gain traction and save the company considerable time otherwise spent on trial and error.

Despite having achieved phased results, NewChuang Medical has not stopped there.

In the future, the company will further strengthen its technological barriers and build a comprehensive product portfolio in the field of neurointervention, while deepening the research and development of innovative products in the coronary and peripheral vascular fields. In addition, Newcare Medical will actively expand into international markets and promote the overseas launch of products such as anticoagulant flow-diverting dense-mesh stents, with the aim of providing more clinically valuable medical devices for the pan-vascular interventional and implantable fields.